85 related articles for article (PubMed ID: 26483198)
21. Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.
Kim YW; Kim YK; Lee JY; Chang KT; Lee HJ; Kim DK; Sheen YY
Xenobiotica; 2008 Mar; 38(3):325-39. PubMed ID: 18274960
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti-cardiac fibrosis activity.
Yang YX; Guo J; Liu C; Nan JX; Wu YL; Jin CH
Arch Pharm (Weinheim); 2024 Apr; ():e2400131. PubMed ID: 38678538
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of novel thiazole-derivatives as potent ALK5 inhibitors.
Arai M; Hanada M; Moriyama H; Ohmoto H; Miyake T; Naka K; Sawa M
Bioorg Med Chem Lett; 2024 Aug; 108():129797. PubMed ID: 38759932
[TBL] [Abstract][Full Text] [Related]
24. Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology.
Ling LE; Lee WC
Curr Pharm Biotechnol; 2011 Dec; 12(12):2190-202. PubMed ID: 21619541
[TBL] [Abstract][Full Text] [Related]
25. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
[TBL] [Abstract][Full Text] [Related]
26. An Angle on MK2 Inhibition-Optimization and Evaluation of Prevention of Activation Inhibitors.
Hedström U; Norberg M; Evertsson E; Lever SR; Munck Af Rosenschöld M; Lönn H; Bold P; Käck H; Berntsson P; Vinblad J; Liu J; Welinder A; Karlsson J; Snijder A; Pardali K; Andersson U; Davis AM; Mogemark M
ChemMedChem; 2019 Oct; 14(19):1701-1709. PubMed ID: 31325352
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine RORγt Inverse Agonists.
Hintermann S; Guntermann C; Mattes H; Carcache DA; Wagner J; Vulpetti A; Billich A; Dawson J; Kaupmann K; Kallen J; Stringer R; Orain D
ChemMedChem; 2016 Dec; 11(24):2640-2648. PubMed ID: 27902884
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors.
Bracht C; Hauser DR; Schattel V; Albrecht W; Laufer SA
ChemMedChem; 2010 Jul; 5(7):1134-42. PubMed ID: 20473979
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, anti-inflammatory, p38α MAP kinase inhibitory activities and molecular docking studies of quinoxaline derivatives containing triazole moiety.
Tariq S; Alam O; Amir M
Bioorg Chem; 2018 Feb; 76():343-358. PubMed ID: 29227918
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as TGF-β Type I Receptor Kinase Inhibitors.
Zhao LM; Guo Z; Xue YJ; Min JZ; Zhu WJ; Li XY; Piao HR; Jin CH
Molecules; 2018 Dec; 23(12):. PubMed ID: 30572609
[TBL] [Abstract][Full Text] [Related]
31. Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.
Heider F; Ansideri F; Tesch R; Pantsar T; Haun U; Döring E; Kudolo M; Poso A; Albrecht W; Laufer SA; Koch P
Eur J Med Chem; 2019 Aug; 175():309-329. PubMed ID: 31096153
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors.
Wang H; Lawson JD; Scorah N; Kamran R; Hixon MS; Atienza J; Dougan DR; Sabat M
Bioorg Med Chem Lett; 2016 Sep; 26(17):4334-9. PubMed ID: 27460209
[TBL] [Abstract][Full Text] [Related]
33. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2.
Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Lane W; Sang BC; Saikatendu K; Matsunaga S; Miwatashi S
ChemMedChem; 2019 Dec; 14(24):2093-2101. PubMed ID: 31697454
[TBL] [Abstract][Full Text] [Related]
34. Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3.
Muth F; El-Gokha A; Ansideri F; Eitel M; Döring E; Sievers-Engler A; Lange A; Boeckler FM; Lämmerhofer M; Koch P; Laufer SA
J Med Chem; 2017 Jan; 60(2):594-607. PubMed ID: 27977190
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological activity of 2-cyanoacrylamide derivatives tethered to imidazopyridine as TAK1 inhibitors.
Kang SJ; Lee JW; Song J; Park J; Choi J; Suh KH; Min KH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1928-1936. PubMed ID: 33086897
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors.
Tan B; Zhang X; Quan X; Zheng G; Li X; Zhao L; Li W; Li B
Bioorg Med Chem Lett; 2020 Aug; 30(16):127339. PubMed ID: 32631540
[TBL] [Abstract][Full Text] [Related]
37. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of the HIF-1α inhibitory activity of 3(5)-substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles as inhibitors of ALK5.
Li YW; Li XY; Li S; Zhao LM; Ma J; Piao HR; Jiang Z; Jin CH; Jin X
Bioorg Med Chem Lett; 2020 Jan; 30(2):126822. PubMed ID: 31810777
[TBL] [Abstract][Full Text] [Related]
39. Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
Engler TA; Henry JR; Malhotra S; Cunningham B; Furness K; Brozinick J; Burkholder TP; Clay MP; Clayton J; Diefenbacher C; Hawkins E; Iversen PW; Li Y; Lindstrom TD; Marquart AL; McLean J; Mendel D; Misener E; Briere D; O'Toole JC; Porter WJ; Queener S; Reel JK; Owens RA; Brier RA; Eessalu TE; Wagner JR; Campbell RM; Vaughn R
J Med Chem; 2004 Jul; 47(16):3934-7. PubMed ID: 15267232
[TBL] [Abstract][Full Text] [Related]
40. From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors.
Heider F; Haun U; Döring E; Kudolo M; Sessler C; Albrecht W; Laufer S; Koch P
Molecules; 2017 Oct; 22(10):. PubMed ID: 29036906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
